Back to results
US 11,541,113 B2Granted
Human cytomegalovirus vaccine
AssigneeModernaTX, Inc.
InventorsGiuseppe Ciaramella, Shinu John
Life of this patent
Estimating the term…
Abstract
The disclosure relates to HCMV ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
Claims17
A method of treating an immunocompromised organ transplant recipient subject having a cytomegalovirus (CMV) infection, comprising administering to the subject a therapeutically effective amount of:
- (i) an HCMV vaccine comprising an RNA polynucleotide having an open reading frame encoding HCMV antigenic polypeptide pp65, and
- (ii) an HCMV vaccine comprising at least one RNA polynucleotide having one or more open reading frames encoding HCMV antigenic polypeptides gH, gL, UL128, UL130, and/or UL131A;
- and an RNA polynucleotide having an open reading frame encoding HCMV antigenic polypeptide gB;
- wherein the HCMV vaccine of (i) and the HCMV vaccine of (ii) are formulated within cationic lipid nanoparticles, and wherein the lipid nanoparticles comprise a molar ratio of 20-60% ionizable cationic lipid, 5-25% non-cationic lipid, 25-55% sterol, and 0.5-15% PEG-modified lipid.
1 more element
Dependencies are inferred from the claim text.